Hyperglycemia, hyperlipidemia and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocininduced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body weight and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of non-diabetic platelets was elevated in the presence of 5x10 -8 mol/L KP-13. This effect was less expressed in the diabetic animals. The effectivity of RF-9 was stronger than that of in non-diabetic platelets, however, it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5x10 -8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.
peptide family. The biologically active forms (KP-54, KP-14, KP-13, KP-10), produced by matrix metalloproteinase (Pinilla et al. 2012; Tena-Sempere 2013) can bind to their own receptors (Kirby et al. 2010) . One of these is the GPR54 receptor that by activating the Gq/11, the ERK1/2 and the p38 MAP kinase signaling pathways (Castaño et al. 2009 ) might play a role in several intracellular processes. This receptor is antagonized by KP-234 (Roseweir et al. 2009 ). Another receptor type is the neuropeptide FF (NPFF) receptors (Elhabazi et al. 2013; Lyubimov et al. 2010 ) that can be coupled to Gi/o proteins leading to the inhibition of adenylate cyclase and resulting in the reduction of cytoplasmic cAMP concentration (Mollereau et al. 2002) . RF-9 is a synthetic peptide that might have a potentially antagonistic effect on KP-13 (Simonin et al. 2006) . Kisspeptins can participate in the regulation of the reproductive axis (Colledge 2009), the cardiovascular system (Maguire et al. 2011; Mead et al. 2007; Mezei et al. 2015; Sawyer et al. 2011) , hemostasis (Qureshi and Kanwal 2011), food intake (Dudek et al. 2016; Hussain et al. 2015; Rao et al. 2013; Tolson et al. 2014; Wahab et al. 2013 ) and various metabolic pathways (Silvestre et al. 2008; Song et al. 2014 ).
D r a f t
Diabetes mellitus is characterized by abnormal carbohydrate, lipid and protein metabolism. These pathophysiological processes result in hyperglycemia, dyslipidemia, overproduction of ROS and inflammatory mediators. These changes can induce endothelial dysfunction, atherosclerosis, platelet activation and pro-thrombotic condition (Hess et al.
2012
; Roffi et al. 2011; Randriamboavonjy 2015) .
The presence of the kisspeptin system was detected also in atherosclerosis-prone vessels (Mead et al. 2007 ) and in the developed edema (Sawyer et al. 2011) . The latter was antagonized by cyclooxygenase inhibition. A recent publication reported that kisspeptin has an anticoagulant activity that might be mediated through changes in Ca signaling, consequently leading to a decreased thrombin concentration and platelet number reduction In our earlier experiment we detected an elevated eicosanoid synthesis of rat platelets, in the presence of KP-13 (Mezei et al. 2015) .
Therefore, in the present study we aimed to investigate the effect of KP-13 (a biologically active form of kisspeptin that binds to both GPR54 and NPFF receptors) and its presumed antagonist, RF-9 peptide, on the platelet aggregation of streptozotocin-induced diabetic rats. 
Animals
Animal experiments were performed under a protocol accepted by the Ethical
Committee for the Protection of Animals in Research at the University of Szeged, Hungary.
All experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Streptozotocin (STZ) was used to induce diabetes in Wistar-Kyoto male rats (weighing 210-230 g, n=6 animals). 65 mg STZ was dissolved in 2 mL of 10% (w/v) sucrose prepared just before the use. The intraperitoneal injection of STZ (65mg/kg) was repeated three days later, using the same dose. Non-diabetic rats (weighing 210-230 g, n=6 animals)
were injected with the solvent as vehicle. After STZ injection, the drinking-water of animals was changed for 10% (w/v) sucrose solution for 24 hours (Furman 2015) . The animals were maintained on 12-h dark/12-h light cycles in a room at constant temperature (23 ± 1 °C) with free access to standard laboratory food and water ad libitum.
We monitored the serum glucose levels, the food and fluid intake, the weight and the urine volume of the animals during the development of diabetes. optimal results and an internal quality control, since two parallel measurements are carried out at the same time. Testing whole blood eliminates the need for time-consuming sample preparation while the natural physiological milieu for platelet function is well-maintained.
Only a small quantity (300 µL) of whole blood is required per test. The aggregometer is capable of performing 5 measurements simultaneously.
The interpretation of the aggregation curve
The aggregation curve is the quantitative display of the reaction and it represents the rate of aggregation ( 
The inducers of the reaction
The manufacturer of the aggregometer provides an array of inducers that provoked platelet aggregation. Using the different inducers the pathways of platelet activation can be examined separately, providing a useful tool in diagnostics, regarding platelet disorders and drug effects. In our current study we used 3 inducers: arachidonic acid, ADP and collagen.
The inducers are marketed in a lyophilized form. Before usage 1 mL ion-free water had to be added carefully, avoiding foam generation. After 10 minutes standing at room temperature, the solution was ready to use.
Performing a measurement

Preparation of blood samples
Whole blood was collected from the abdominal aorta of anesthetized (Euthasol® 30 mg/body weight i.p.) rats with a thick needle and drawn into a plastic tube, containing 15 µg/mL hirudin (Tóth 2006) . The specimens were gently mixed by hand with end-over-end inversion for three to six times, and transported to the laboratory at room temperature. The aggregometric examination was carried out within one and a half hours after the collection of blood (Sweeney 1989 ).
The platelet count of specimens was determined and standardized. All of the aggregometric cuvettes contained the same number of platelets (250-350 x 10 9 platelets/L).
When the platelet count of the sample was higher, it was diluted by own platelet-poor plasma.
If the sample contained fewer platelets, we applied a greater amount of blood and less amount of 0.9% NaCl solution in the aggregometric cuvette. The platelet count was also measured after the aggregation in order to detect potential thrombocytolysis.
The total volume of a test cuvette is 620 µL. According to the original measurement protocol of the device, the solution contains the following: 300 µL whole blood, 300 µL 0.9% NaCl solution and 20 µL inducer. The investigated peptides are not included in this protocol, hence we had to modify the composition of the solution. We used the aggregometer in a semi- 
Examining the effect of inducers on rat platelets
At first we assessed the control effect of inducers. 300 µL whole blood and 300 µL 0.9% NaCl solution were added into the test cuvette. After 3 minutes of incubation outside the aggregometer, the cuvette was attached to the device and another 3 minutes of incubation was performed. Then the aggregation reaction was initiated by administering 20 µL of inducer (ADP, arachidonic acid or collagen). The measurement was performed with all three inducers in each animal.
Examining the effect of peptides on rat platelets
KP-13 (the presumed agonist) and RF-9 (the presumed antagonists) were investigated.
The following peptide concentrations were applied: 0; 1.25 x 10 -8 ; 2.5 x 10 -8 ; 5 x 10 -8 ; 10 x 10 -8 mol/L.
We examined the sole effect of each peptide. In these experimental arrangements 20 µL peptide was added to 300 µL blood and 280 µL saline. After 3 minutes of incubation outside the aggregometer, the cuvette was attached to the device and another 3 minutes of incubation was performed. Then the aggregation reaction was initiated by administering 20 µL of inducer (ADP, arachidonic acid or collagen). The measurement was performed with all three inducers on every animal's blood samples.
To verify the antagonistic activity of RF-9, the sample had to be pre-incubated with one of the aforementioned peptides before the addition of KP-13. 20 µL RF-9 was added to 300 µL blood diluted with 260 µL saline. After 3 minutes of incubation the test cell was attached to the aggregometer, and KP-13 was added. The reaction was initiated after another 3 minutes of incubation by administering 20 µL of inducer (ADP, arachidonic acid or collagen).
The measurement was performed with all three inducers on every animal's blood samples.
Statistical analysis
The results are expressed as means ± SE. The significance of the differences between the platelet aggregation of the peptide-treated and untreated platelets in diabetic or nondiabetic rats was determined by one-way analysis of variance, followed by Tukey's multiple comparison post hoc test. This statistical analysis was also carried out at the same peptide concentration between the diabetic and non-diabetic groups. A difference at a level P <0.05
was considered statistically significant. The statistical analysis was performed by SPSS 
RESULTS
The development of STZ-induced diabetes in male rats was confirmed by a significant elevation in water drinking (from 263.8 ± 10.1 mL/week to 938 ± 49.9 mL/week) and in food intake (from 202.2 ± 3.2 to 224 ± 5.2 g/week) ( Table 1) . Parallel with this, we detected a 40.2% reduction in bodyweight and 43.4% elevation in urine formation in diabetic animals compared to the non-diabetic, control rats ( Table 1 ).
The development of diabetes mellitus was also verified by the significant increase in serum glucose level, from 9.5 ± 0.45 mmol/L to 25.4 ± 0.88 mmol/L ( 6.9 ± 0.27 mmol/L) levels of diabetic rats were also significantly elevated, compared to those of non-diabetic animals. These parameters were higher than the normal values published by Charles River Laboratories, while the serum triglyceride was elevated (1.5 ± 0.27 vs. 0.9 ± 0.1 mmol/L) only when we compared it to the values of non-diabetic rats (Table 2) . D r a f t 13 three characteristic parameters of the aggregation curves (area under the curve, maximal aggregation, speed of aggregation). All these parameters were found to be the highest in case of collagen-induced platelet aggregation in both animal groups (Table 4) .
Therefore, we examined the effect of KP-13 and RF-9 on the collagen-induced aggregation of non-diabetic and diabetic rat platelets. 5 x 10 -8 mol/L KP-13 induced significant increase in non-diabetic rat platelet aggregation compared to the peptide-free controls. This effect is represented by an increase in AUC (from 56.9 ± 3.26 to 69.73 ± 3.27 U), an elevation in MA (from 78.33 ± 4.2 to 97.39 ± 4.19 AU) and in SA (from 23.49 ± 1.67 to 28.21 ± 1.68 AU/min) ( Fig. 1/A) . Although we increased the peptide concentration further, no augmentation of platelet aggregation was observed (i.e. we obtained a plateau-shaped dose-response curve). Since in the presence of KP-13 we detected significant elevation (by 22%) only in case of maximal aggregation, an increased platelet aggregability of diabetic rats could not be sufficiently demonstrated in vitro ( Fig. 1/B ). The speed of the collagen-induced aggregation of non-diabetic platelets was significantly increased by 5x10 -8 KP-13 (28.21 ± 1.68 AU/min, Fig. 1/A ), compared to diabetic rats (22.8 ± 1.76 AU/min, Fig. 1/B ).
When we tested RF-9, a presumed kisspeptin antagonist, we detected significant augmentation of platelet aggregation in non-diabetic rats ( The platelet aggregation increasing effect of 5 x 10 -8 mol/L KP-13 was not prevented by the pre-treatment with various concentrations of RF-9 (Fig. 3) . The aggregability of nondiabetic platelets was significantly higher than that of diabetic animals already at 2.5 x 10 It has already been published that the hyper-reactivity of platelets is an important complication during diabetes mellitus (Ferreiro and Angiolillo 2011; Randriamboavonjy et al. 2014; Roffi et al. 2011) . The hyper-reactivity of thrombocytes may be induced also indirectly.
In this case the diabetic endothelial dysfunction (releasing platelet activator factors and expressing adhesion receptors) can indirectly result in platelet activation (Paneni et al. 2013; Yeom et al. 2016 producing ROS (Tang et al. 2014 ) and activating the p38/MAP kinase pathway (Tang et al. 2011 ), leads to platelet adhesion, aggregation and secretion. An elevated serum glucose level also leads to the formation of advanced glycation end-products, and it can stimulate platelet receptor expression and secretion (Gawlowski et al. 2009 ). Moreover, it has already been demonstrated that the low insulin level also results in platelet activation (Ferreira et al. 2006 ).
Dyslipidemia (elevated LDL, decreased HDL) can stimulate thromboxane synthesis, due to the increased intracellular calcium level (Pedreno et al. 2001; Siewiera et al. 2016 ).
The apoptosis of thrombocytes by oxidative stress has already been reported by Leytin (2012). These processes, alone or together, might play a role in the in vivo activation of circulating blood platelets, which may explain the platelet number reduction in diabetic rats in the present experiments. Yeom et al. also reported (2016) the elevated adhesion of platelets and the reduction of platelet number in diabetic rats in a time-dependent manner.
We detected that collagen was the most effective inducer for the ex vivo examination of platelet aggregation, however, we could not find significant difference between the diabetic and non-diabetic platelet aggregability. The application of this inducer is supported by the fact that collagen plays an important role in those pathological conditions in which endothelial dysfunction participates. The similar ex vivo reaction of the diabetic and non-diabetic platelets might be explained by the period of time elapsing after the induction of diabetes. This is supported by the fact that the effect of diabetes on platelet function (e.g. thromboxane synthesis and adhesion) is also time-dependent (Siewiera et al. 2016; Yeom et al. 2016 ).
In addition to its several other effects, kisspeptin can prolong the bleeding time and reduce the number of platelets in rats. This was detected when KP-13 was applied D r a f t intraperitoneally in vivo (Qureshi and Kanwal 2011). In our earlier experiments we detect an in enhancement of thromboxane (a potent vasoconstrictor and platelet aggregator) synthesis of rat platelets in the presence of KP-13 (Mezei et al. 2015) . In our present study we observed that KP-13 enhanced the aggregation of non-diabetic platelets in a dose-dependent manner, in the presence of collagen, as inducer. On the other hand, this effect was only moderate in diabetic thrombocytes. It has already been reported that kisspeptin (binding to the G-protein coupled receptor and activating several intracellular processes) can induce the elevation of intracellular calcium ion (Kotani et al. 2001; Cvetković et al. 2013 ). We may suggest that the KP-13-induced increase of non-diabetic platelet aggregation is mediated by elevated intracellular calcium ion level, because it participates in the activation of thromboxane synthesis, the degranulation and the receptor expression of platelets. These processes alone and together can support and accelerate the aggregation process (Li et al. 2010) . We may think that the reduced ex vivo aggregability of diabetic platelets to KP-13 is explained by the in vivo activation of diabetic platelets, which is demonstrated by the degranulation of thrombocytes, the glycation of receptors and the alteration of membrane fluidity (Randriamboavonjy et al. 2014) . On the other hand, it has already been reported that the glycation of cyclooxygenase enzyme (Angiolillo 2009 ) and diabetic dyslipidemia (Watala et al. 2005; Kim et al. 2014 ) play a role in the development of aspirin resistance. Simonin et al. (2006) reported that RF-9 binding to the NPFF2R kisspeptin receptor might have a potentially antagonistic effect on KP-13. In this case, RF-9 coupled to Gi/o protein should have resulted in elevated cytoplasmic cAMP and reduced intracellular calcium ion level, and as a result, reduced platelet aggregation. In the present experiment the application of RF-9, even at a lower peptide concentration than KP-13, induced hyperaggregability of non-diabetic platelets.
We assume that RF-9 is likely to have an effect not only on NPFF2, but also on another receptor. This is also supported by Maletínská et al. (2013) reporting that RF-9 is a partial D r a f t 18 agonist of kisspeptin receptor, and Min et al. (2015) discussing RF-9 as a kisspeptin receptor agonist. In our experiment using a pre-treatment with RF-9, we could not verify its antagonistic effect on kisspeptin, moreover, we demonstrated a synergy with KP-13. Our results can be supported by the data published by Kim et al. (2015) reporting that RF-9, the presumed antagonists of NPFF1R is in fact the agonist of both NPFF1R and the kisspeptin receptor (KISS1R). The reason for the fact that the RF-9 pre-treatment induced even stronger platelet activation (compared to the case when only kisspeptin was used), can be found in that the elevation of the ic. Ca 2+ level induced by RF-9 may augment the expression of the platelet receptors (e.g. KISS1R) (Min et al. 2014; Babwah et al. 2012) . Exploring the mechanism of these diverging receptorial effects requires further investigations.
In conclusion, it has been demonstrated that KP-13 was able to enhance ex vivo collagen-induced aggregability of non-diabetic rat platelets in a dose-dependent manner in which the enhancement of thromboxane synthesis (as our team has already published) may also play a role (Mezei et al. 2015) . Streptozocin-induced experimental diabetes in rats did not induce significant change in the collagen-induced aggregability of platelets in vitro. This may be explained by the long lasting in vivo activation of platelets during the development of diabetes and their structural and functional impairment. Under these experimental conditions RF-9 did not prove to be an antagonist of KP-13, moreover, it potentiated the platelet aggregation. 
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